Short Interest in Nutriband Inc. (NASDAQ:NTRB) Drops By 51.1%

Nutriband Inc. (NASDAQ:NTRB) saw a large drop in short interest in October. As of October 31st, there was short interest totalling 41,800 shares, a drop of 51.1% from the October 15th total of 85,400 shares. Currently, 0.9% of the company’s stock are short sold. Based on an average trading volume of 32,900 shares, the days-to-cover ratio is presently 1.3 days.

Hedge Funds Weigh In On Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Virtu Financial LLC acquired a new position in Nutriband Inc. (NASDAQ:NTRB) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,862 shares of the company’s stock, valued at approximately $58,000. Virtu Financial LLC owned about 0.12% of Nutriband as of its most recent SEC filing. 19.70% of the stock is owned by institutional investors.

Nutriband Stock Down 4.8 %

NASDAQ:NTRB traded down $0.24 during mid-day trading on Wednesday, hitting $4.81. 19,319 shares of the company’s stock were exchanged, compared to its average volume of 35,255. Nutriband has a one year low of $2.04 and a one year high of $9.60. The business has a fifty day moving average price of $5.84 and a 200 day moving average price of $5.57. The company has a market cap of $53.44 million, a PE ratio of -5.72 and a beta of 1.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.57 and a quick ratio of 6.36.

Nutriband (NASDAQ:NTRB) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.12) earnings per share for the quarter. Nutriband had a negative net margin of 401.39% and a negative return on equity of 66.60%. The company had revenue of $0.44 million for the quarter.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.